Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
7
×
life sciences
national blog main
national top stories
boston top stories
deals
new york blog main
startups
biotech
clinical trials
new york top stories
san francisco blog main
san francisco top stories
boston
cancer
crispr
detroit blog main
detroit top stories
fda
gene therapy
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
boulder/denver blog main
boulder/denver top stories
funding
gene editing
glaxosmithkline
indiana blog main
indiana top stories
ipo
What
years
7
×
medicines
ago
bio
therapeutics
crispr
deal
gene
ipo
new
roundup
sciences
acquisitions
adding
address
adds
admits
age
aiming
allogene
allosteric
announced
balance
big
bigger
biggest
biotechs
build
cancer
ceo
classes
clinic
collabs
combinator
come
companies
covid
create
daniel
decibel
Language
unset
Current search:
photo
×
years
×
" boston blog main "
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More